Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use

Addiction

Volumn 109, Issue 11, 2014, Pages 1878-1886

  Heinzerling, Keith G ^a   Swanson, Aimee Noelle ^a   Hall, Timothy M ^a   Yi, Yi ^a   Wu, Yingnian ^a   Shoptaw, Steven J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bupropion; Clinical trial; Medication non adherence; Methamphetamine; Pharmacotherapy; Placebo

Indexed keywords

AMFEBUTAMONE; DOPAMINE UPTAKE INHIBITOR; METHAMPHETAMINE;

ADULT; AMPHETAMINE-RELATED DISORDERS; BLOOD; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADULT; AMPHETAMINE-RELATED DISORDERS; BUPROPION; DOPAMINE UPTAKE INHIBITORS; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; METHAMPHETAMINE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84908053593     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12636     Document Type: Article

References (42)

1. Brensilver M., Heinzerling K. G., Shoptaw S. Pharmacotherapy of amphetamine-type stimulant dependence: an update. Drug Alcohol Rev 2013; 32: 449-460.
2. Lee N. K., Rawson R. A. A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug Alcohol Rev 2008; 27: 309-317.
3. Dean A. C., London E. D., Sugar C. A., Kitchen C. M., Swanson A. N., Heinzerling K. G. etal. Predicting adherence to treatment for methamphetamine dependence from neuropsychological and drug use variables. Drug Alcohol Depend 2009; 105: 48-55.
4. Roll J. M., Petry N. M., Stitzer M. L., Brecht M. L., Peirce J. M., McCann M. J. etal. Contingency management for the treatment of methamphetamine use disorders. Am J Psychiatry 2006; 163: 1993-1999.
5. Vearrier D., Greenberg M. I., Miller S. N., Okaneku J. T., Haggerty D. A. Methamphetamine: history, pathophysiology, adverse health effects, current trends, and hazards associated with the clandestine manufacture of methamphetamine. Dis Mon 2012; 58: 38-89.
6. Simmler L. D., Wandeler R., Liechti M. E. Bupropion, methylphenidate, and 3, 4-methylenedioxypyrovalerone antagonize methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence. BMC Res Notes 2013; 6: 220-224.
7. Rau K. S., Birdsall E., Hanson J. E., Johnson-Davis K. L., Carroll F. I., Wilkins D. G. etal. Bupropion increases striatal vesicular monoamine transport. Neuropharmacology 2005; 49: 820-830.
8. Reichel C. M., Murray J. E., Grant K. M., Bevins R. A. Bupropion attenuates methamphetamine self-administration in adult male rats. Drug Alcohol Depend 2009; 100: 54-62.
9. Schindler C. W., Gilman J. P., Panlilio L. V., McCann D. J., Goldberg S. R. Comparison of the effects of methamphetamine, bupropion, and methylphenidate on the self-administration of methamphetamine by rhesus monkeys. Exp Clin Psychopharmacol 2011; 19: 1-10.
10. Newton T. F., Roache J. D., De La Garza R. II, Fong T., Wallace C. L., Li S. H. etal. Safety of intravenous methamphetamine administration during treatment with bupropion. Psychopharmacology (Berl) 2005; 182: 426-435.
11. Newton T. F., Roache J. D., De La Garza R. 2nd, Fong T., Wallace C. L., Li S. H. etal. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 2006; 31: 1537-1544.
12. Nomikos G. G., Damsma G., Wenkstern D., Fibiger H. C. Acute effects of bupropion on extracellular dopamine concentrations in rat striatum and nucleus accumbens studied by in vivo microdialysis. Neuropsychopharmacology 1989; 2: 273-279.
13. Egerton A., Shotbolt J. P., Stokes P. R., Hirani E., Ahmad R., Lappin J. M. etal. Acute effect of the anti-addiction drug bupropion on extracellular dopamine concentrations in the human striatum: an [11C]raclopride PET study. Neuroimage 2010; 50: 260-266.
14. Lee B., London E. D., Poldrack R. A., Farahi J., Nacca A., Monterosso J. R. etal. Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J Neurosci 2009; 29: 14734-14740.
15. Argyelan M., Szabo Z., Kanyo B., Tanacs A., Kovacs Z., Janka Z. etal. Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study. J Affect Disord 2005; 89: 115-123.
16. Meyer J. H., Goulding V. S., Wilson A. A., Hussey D., Christensen B. K., Houle S. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl) 2002; 163: 102-105.
17. Mansvelder H. D., Fagen Z. M., Chang B., Mitchum R., McGehee D. S. Bupropion inhibits the cellular effects of nicotine in the ventral tegmental area. Biochem Pharmacol 2007; 74: 1283-1291.
18. Glick S. D., Sell E. M., Maisonneuve I. M. Brain regions mediating alpha3beta4 nicotinic antagonist effects of 18-MC on methamphetamine and sucrose self-administration. Eur J Pharmacol 2008; 599: 91-95.
19. Dwoskin L. P., Crooks P. A. A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. Biochem Pharmacol 2002; 63: 89-98.
20. Elkashef A. M., Rawson R. A., Anderson A. L., Li S. H., Holmes T., Smith E. V. etal. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology 2008; 33: 1162-1170.
21. Shoptaw S., Heinzerling K. G., Rotheram-Fuller E., Steward T., Wang J., Swanson A. N. etal. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend 2008; 96: 222-232.
22. McCann D. J., Li S. H. A novel, nonbinary evaluation of success and failure reveals bupropion efficacy versus methamphetamine dependence: reanalysis of a multisite trial. CNS Neurosci Ther 2012; 18: 414-418.
23. Anderson A. L., Li S. H., Biswas K., McSherry F., Holmes T., Iturriaga E. etal. Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend 2012; 120: 135-141.
24. Somoza E. C., Winship D., Gorodetzky C. W., Lewis D., Ciraulo D. A., Galloway G. P. etal. A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence. JAMA Psychiatry 2013; 70: 630-637.
25. Stout R. L., Wirtz P. W., Carbonari J. P., Del Boca F. K. Ensuring balanced distribution of prognostic factors in treatment outcome research. J Stud Alcohol 1994; 12: 70-75.
26. Kessler R. C., Green J. G., Adler L. A., Barkley R. A., Chatterji S., Faraone S. V. etal. Structure and diagnosis of adult attention-deficit/hyperactivity disorder: analysis of expanded symptom criteria from the Adult ADHD Clinical Diagnostic Scale. Arch Gen Psychiatry 2010; 67: 1168-1178.
27. Heinzerling K. G., Swanson A. N., Kim S., Cederblom L., Moe A., Ling W. etal. Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend 2010; 109: 20-29.
28. Spitzer R., Williams J., Gibbbon M., First M. The Structured Clinical Interview for DSM-IV. Washington, DC: American Psychiatric Press; 1995.
29. McLellan A. T., Kushner H., Metzger D., Peters R., Smith I., Grissom G. etal. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 1992; 9: 199-213.
30. Sobell M. B., Sobell L. C., Klajner F., Pavan D., Basian E. The reliability of a timeline method for assessing normal drinker college students' recent drinking history: utility for alcohol research. Addict Behav 1986; 11: 149-161.
31. McGregor C., Srisurapanont M., Mitchell A., Longo M. C., Cahill S., White J. M. Psychometric evaluation of the Amphetamine Cessation Symptom Assessment. J Subst Abuse Treat 2008; 34: 443-449.
32. Williams J. B. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry 1988; 45: 742-747.
33. Patton J. H., Stanford M. S., Barratt E. S. Factor structure of the Barratt impulsiveness scale. J Clin Psychol 1995; 51: 768-774.
34. Carroll K. M., Kiluk B. D., Nich C., Devito E. E., Decker S., Lapaglia D. etal. Toward empirical identification of a clinically meaningful indicator of treatment outcome: features of candidate indicators and evaluation of sensitivity to treatment effects and relationship to one year follow up cocaine use outcomes. Drug Alcohol Depend 2014; 137c: 3-19.
35. Rubin D. B. Multiple Imputation for Nonresponse in Surveys. Hoboken, NJ: Wiley-Interscience; 2004.
36. Abraham A. J., Roman P. M. Early adoption of injectable naltrexone for alcohol-use disorders: findings in the private-treatment sector. J Stud Alcohol Drugs 2010; 71: 460-466.
37. Pettinati H. M., Weiss R. D., Dundon W., Miller W. R., Donovan D., Ernst D. B. etal. A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. J Stud Alcohol 2005; 15: 170-178; discussion 168-179.
38. Herron A. J., Mariani J. J., Pavlicova M., Parrinello C. M., Bold K. W., Levin F. R. etal. Assessment of riboflavin as a tracer substance: comparison of a qualitative to a quantitative method of riboflavin measurement. Drug Alcohol Depend 2013; 128: 77-82.
39. Finitsis D. J., Pellowski J. A., Johnson B. T. Text message intervention designs to promote adherence to antiretroviral therapy (ART): a meta-analysis of randomized controlled trials. PLOS ONE 2014; 9: e88166.
40. Galloway G. P., Coyle J. R., Guillén J. E., Flower K., Mendelson J. E. A simple, novel method for assessing medication adherence: capsule photographs taken with cellular telephones. J Add Med 2011; 5: 170-174. doi: 10.1097/ADM.0b013e3181fcb5fd.
41. Brensilver M., Heinzerling K. G., Swanson A. N., Shoptaw S. J. A retrospective analysis of two randomized trials of bupropion for methamphetamine dependence: suggested guidelines for treatment discontinuation/augmentation. Drug Alcohol Depend 2012; 125: 169-172.
42. Perkins K. A., Lerman C. An efficient early phase 2 procedure to screen medications for efficacy in smoking cessation. Psychopharmacology (Berl) 2014; 231: 1-11.